Neurology-Neuroimmunology & Neuroinflammation, published by LIPPINCOTT WILLIAMS & WILKINS, stands at the forefront of research in the rapidly evolving fields of neurology and neuroimmunology. Since its inception in 2014, this prestigious journal has embraced an Open Access model, ensuring that groundbreaking findings are readily available to researchers, clinicians, and students worldwide. Covering a broad spectrum of topics related to neuroinflammation, the journal has gained a remarkable reputation, attaining a Q1 ranking in both Neurology and Neurology (clinical) as of 2023, and ranking #6 out of 192 in the neuroscience category on Scopus. The journal's commitment to high-quality research aims to facilitate the understanding of neurological disorders, promote innovative therapies, and inspire collaboration among professionals. Addressing critical issues at the intersection of neurology, immunology, and clinical practice, Neurology-Neuroimmunology & Neuroinflammation is an essential platform for the dissemination of knowledge and the advancement of this vital field.

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

The Revista Mexicana de Neurociencia, published by the ACAD MEXICANA NEUROLOGIA, serves as a pivotal platform for the dissemination of research within the field of neurology and neuroscience. Although it was active from 2008 to 2014 and is no longer covered in Scopus, the journal still holds a significant place in the academic community, addressing critical topics relevant to both clinical and experimental neurology. With an emphasis on advancing knowledge in neuropsychology and public health, this journal targets researchers, professionals, and students alike, fostering an interdisciplinary dialogue that can enhance the understanding of neurological conditions within Mexico and beyond. As it stands, the journal is not open access, which may present challenges for accessibility, yet its affiliation with recognized academic standards underlines its commitment to quality research. This platform once provided insights that can inform practice and stimulate innovative approaches in the management of neurological disorders, underscoring its importance in the evolving landscape of neuroscience.

The Journal of Neuroimmune Pharmacology, published by Springer, is a premier academic journal dedicated to advancing the field of pharmacology intersecting with neuroscience and immunology. With an outstanding impact factor and proudly positioned in the Q1 quartile across multiple categories, this journal showcases cutting-edge research that enhances our understanding of the neuroimmune system and its pharmacological implications. Established in 2006 and continuing through 2024, it serves as a vital resource for researchers, professionals, and students alike, offering insights into the mechanisms of drug action, disease processes, and therapeutic strategies. As a testament to its excellence, the journal ranks prominently in Scopus metrics within its discipline, making it an essential platform for disseminating high-quality research that drives innovation in immunology, allergy, neuroscience, and pharmacology.

Expert Review of Neurotherapeutics is an esteemed journal published by Taylor & Francis Ltd, focusing on the rapidly evolving field of neurotherapeutics. With an ISSN of 1473-7175 and an E-ISSN of 1744-8360, this publication aims to bridge the gap between clinical and preclinical research, providing a platform for innovative therapeutic strategies in neurology and neuroscience. The journal boasts impressive impact factor rankings, categorized as Q2 in both clinical neurology and miscellaneous neuroscience, and Q1 in medical pharmacology for 2023. Its reputable placement in Scopus rankings, including Rank #82/400 in clinical neurology, underscores its significance within the medical research community. Spanning from 2001 to 2024, the journal publishes critical reviews and original research articles aimed at enhancing understanding and treatment in neurological disorders. Although it currently does not offer open access, articles published in the journal are crucial for researchers, healthcare professionals, and students seeking to stay at the forefront of advancements in neurotherapeutics. With its strong emphasis on rigorous peer-reviewed content, Expert Review of Neurotherapeutics continues to be a vital resource for those dedicated to improving patient outcomes in the realm of neurology.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

INFLAMMOPHARMACOLOGY is a premier journal published by SPRINGER BASEL AG, specializing in the evolving fields of immunology and pharmacology. Established in 1991, the journal has made significant strides in contributing to the understanding of inflammation-related disorders, therapeutic innovations, and the pharmacological implications associated with these conditions. With an impressive Q2 ranking in Immunology and Q1 rankings in both Pharmacology and Medical Pharmacology for 2023, alongside notable Scopus rankings, INFLAMMOPHARMACOLOGY maintains its position at the forefront of scientific research. The journal provides a vital platform for researchers and practitioners to disseminate groundbreaking findings and explore novel approaches in therapeutics, reinforcing the importance of evidence-based medicine. Accessible exclusively through traditional subscription options, it continues to attract a diverse readership invested in advancing knowledge within these cutting-edge disciplines.

Nature Reviews Neurology, published by NATURE PORTFOLIO, stands as a leading scholarly journal dedicated to the field of neurology and neuroscience. With an impressive impact factor and a prestigious Q1 categorization in both Cellular and Molecular Neuroscience and Clinical Neurology, this journal provides cutting-edge reviews and insights into the latest research developments, trends, and clinical practices. Based in the United Kingdom and accessible to a global audience, Nature Reviews Neurology aims to foster knowledge dissemination and interdisciplinary collaboration among researchers, healthcare professionals, and educators. With an influential Scopus ranking, it remains a pivotal resource for those seeking to deepen their understanding of neurological disorders and therapies while remaining at the forefront of academic discourse and innovation in the field.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.